Back

Naxos study: risk of bleeding with oral anticoagulants in non-valvular atrial fibrillation patients in France

29 August 2020 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: NOAC Dosing, Adherence and Treatment Effects Oral Anticoagulation ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Nicolas Danchin

Saint Joseph Hospital, Paris (France)

5 More presentations in this session

Presentation thumbnail
The effect of computer decision support on optimizing appropriate dosing of novel oral anticoagulant therapy in the IMPACT-AF study
Doctor J. Cox (Halifax, CA)
Abstract Slides
Presentation thumbnail
Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomised clinical trial
Doctor A. Tzikas (Thessaloniki, GR)
Abstract Slides
Presentation thumbnail
Real-world adherence to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation measured by an electronic medication event monitoring system
Doctor M. Delesie (Gent, BE)
Abstract Slides
Presentation thumbnail
Comparison between non-vitamin K antagonist oral anticoagulants versus warfarin for the risk of dementia in Asian patients with non-valvular atrial fibrillation
Doctor S. Lee (Seoul, KR)
Abstract Slides
Presentation thumbnail
Compliance of atrial fibrillation treatment with the ABC pathway in patients with concomitant diabetes mellitus in the Middle East based on the Gulf SAFE registry
Doctor J. Gumprecht (Zabrze, PL)
Abstract Slides

Access the full session

Session thumbnail
NOAC Dosing, Adherence and Treatment Effects

The Event

Event poster

ESC Congress 2020

29 August - 1 September 2020
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on stroke prevention in atrial fibrillation
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro
thumbnail
Congress Presentation
Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - con

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources